GHK-Cu + BPC-157 Blend
Copper-tripeptide (GHK-Cu) + stable gastric pentadecapeptide (BPC-157) blend
- Class
- Cross-class repair blend
- Half-life
- Both short (hours)
- Route
- Subcutaneous (SubQ)
- Cadence
- Daily
- Evidence
- Mixed / early human
Overview
GHK-Cu + BPC-157 pairs two different repair mechanisms: GHK-Cu (a copper-coordinated tripeptide) drives collagen synthesis, fibroblast activation, and matrix remodelling; BPC-157 drives angiogenesis (new blood vessel growth) and gut-mucosal healing via the VEGFR2/NO pathway. They don't overlap pharmacologically — the combination targets the structural + vascular sides of tissue repair simultaneously.
This blend is less canonical than BPC-157 + TB-500 (which is the 'standard' research-market healing stack). It's used mostly by people targeting skin / connective-tissue work who want injected GHK-Cu in the same regimen as BPC. Topical GHK-Cu is the route with the best human evidence; the injected use is more speculative.
Safety considerations
A few of the safety signals worth knowing — the full list, with dosing context and what to monitor, is inside AIx Core.
- Not approved for human use as a blend. Research-market product.
- Copper-handling disorders (Wilson's disease, hemochromatosis) — hard no for the injected GHK-Cu component. Topical is fine but this blend is sc.
- BPC-157's angiogenesis mechanism is a theoretical concern in active or recent cancer — avoid in that context.
+ 2 more safety notes inside AIx Core →
Commonly monitored
Markers and signals people track when researching GHK-Cu + BPC-157 Blend.
- Skin quality / wound-healing time if treating a specific issue (photos in matched lighting are the best record)
- Plasma copper / ceruloplasmin if dosing long-term sc
- Injection site for blue-green staining (cosmetic; from the copper complex)
- Blood pressure (BPC-157 has mild BP-lowering effect)
- WADA status — GHK-Cu is on the prohibited list; BPC likely covered as 'similar substance'
Frequently asked questions
What is GHK-Cu + BPC-157 Blend?
Copper-tripeptide (GHK-Cu) + stable gastric pentadecapeptide (BPC-157) blend. GHK-Cu + BPC-157 pairs two different repair mechanisms: GHK-Cu (a copper-coordinated tripeptide) drives collagen synthesis, fibroblast activation, and matrix remodelling; BPC-157 drives angiogenesis (new blood vessel growth) and gut-mucosal healing via the VEGFR2/NO pathway. They don't overlap pharmacologically — the combination targets the structural + vascular sides of tissue repair simultaneously.
How is GHK-Cu + BPC-157 Blend administered?
Subcutaneous (SubQ), typically daily.
What is the half-life of GHK-Cu + BPC-157 Blend?
Both short (hours) — GHK-Cu sc ~hours · BPC-157 sc ~4 h. Daily dosing is standard..
Is GHK-Cu + BPC-157 Blend approved for human use?
GHK-Cu + BPC-157 Blend is investigational — not approved by the FDA, EMA, or MHRA for human use at the time of writing.
What does the evidence show for GHK-Cu + BPC-157 Blend?
Evidence tier: Mixed / early human. User reports cluster around joint + skin contexts — knee pain, post-procedure skin recovery, hair density. Effect sizes are small and slow.
What is commonly monitored when researching GHK-Cu + BPC-157 Blend?
Commonly tracked markers + signals: Skin quality / wound-healing time if treating a specific issue (photos in matched lighting are the best record), Plasma copper / ceruloplasmin if dosing long-term sc, Injection site for blue-green staining (cosmetic; from the copper complex), Blood pressure (BPC-157 has mild BP-lowering effect), WADA status — GHK-Cu is on the prohibited list; BPC likely covered as 'similar substance'.
Related compounds
Open this in AIx Core for the full picture
Mechanism breakdown, receptor pathway diagram, full safety list, monitored items, source citations, and one-tap add-to-protocol. Free with any account.